11.2023
Cenexum enters worldwide, exclusive license with Aarhus University covering a bio-electronics platform technology targeting next-generation neuromodulation solutions. As a result, Aarhus University will become a shareholder in Cenexum. The license marks a significant milestone for Cenexum in support of its development of products to address the high unmet needs of patients with severe neurological disorders.
